Cervomed Inc. · NASDAQ:CRVO
Cervomed — Investor Presentation (October 2023)
25 slides from Cervomed's investor presentation, Oct 25, 2023
Slide 1: Corporate Overview: Medicines for the Brain
$ CERVOMED “Medicines for the Brain” Corporate Overview NASDAQ: CRVO October 25th, 2023 cerveau (sair-voh), noun, in French for brain or mind
Slide 2: Forward-Looking Statements
§ CERVOMED Forward-Looking Statements This presentation includes express and implied forward-looking statements within the meaning of the Private Secures Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of Cervoled Inc. (th
Slide 3: CervoMed at a Glance
CervoMed at a Glance § CERVOMED Late Clinical Stage CNS Company Differentiated approach to age-related neurologic disorders with a late-stage lead clinical asset; pipeline of additional indications and second asset Leading drug candidate in major neurologic indication Neflamapimod is poisedto be the
Slide 4: CervoMed Management Team
§ CERVOMED CervoMed Management Team
Slide 5: Non-Employee Directors and Advisors
Non-Employee Directors and Advisors § CERVOMED DIRECTORS ~ : Syie Gregoire, Pharm (Chair) ormer Execute Char and Co-Founder of Pharma * Boar member, Novo Hersek, Rey (th Perkn Ene, F26 + Former Presizert, Human Genetes Therapies, Shee + Former Execute VP, Bogen, CEO, Gyco ‘Former Bosra member at ifr
Slide 6: Dementia with Lewy Bodies (DLB)
Dementia with Lewy Bodies (DLB) What is DLB? + Disease associated with abnormal deposits ofa protein called alph ssynuclein inthe brain. These deposits, called Lewy bodies, affect chemicals in the brain whose changes, in tum, can lead to problems with thinking, ‘movement, behavior, and moodt + Patie
Slide 7: Neflamapimod for DLB: Well-Positioned
Neflamapimod for DLB: Well-Positioned § CERVOMED Commercially Significant Patient ‘Numbers: Approximat Growth in Diagne >$38 Peak : US Sales for First to Market Need / Cholinesterase inhibitors uilized
Slide 8: Neflamapimod Background
Neflamapimod Background $ CERVOMED + Oral small molecule highly selective inhibitor of the protein kinase p38a,, a major activator of the cellular stress response cr cl or oe F + Licensed from Vertex Pharmaceuticals in 2014 NN yAg: F = Vertex had developed through to phase 2a clinical study in rheum
Slide 9: Targeting Synaptic Dysfunction To Treat Neurodegenerative Diseases
Targeting Synaptic Dysfunction To § CERVOMED Treat Neurodegenerative Diseases Why Target Synaptic Dysfunction? m Reversing Synaptic Dysfunction Provides Ability to anasto Mets Enewonel ess, Demonstrate Efficacy in < 6 Month Duration Clinical Study progressive loss of function of eiesana ass synapses
Slide 10: Opportunity for Therapeutics Targeting Basal Forebrain Cholinergic Degeneration
Opportunity for Therapeutics Targeting Basal § CERVOMED Forebrain Cholinergic Degeneration ‘Age-related degeneration of the basal forebrain cholinergic system, the major source of the neurotransmitter acetylcholine, plays major role in many neurologic disorders: + Dementia with Lewy bodies (DLB), wh
Slide 11: Neflamapimod Mechanism of Action
Neflamapimod Mechanism of § CERVOMED Action Neuro- inflammation PP ——a-synuclein to n : = Memory Cholinergic Degeneration [| arm ippoca Perot Basal Forebrain ee, ett APP ~ Amyloid Precursor Protein; NGF Nerve Growth Factor ‘Alam & Nixon, Molecular Neurodegeneration, 2023 10
Slide 12: Nature Communications Article
Nature Communications Article “The authors show in an animal model and ina study in patients with dementia with Lewy bodies (DLB) that the drug neflamapimod has potential to treat diseases, such as DLB, associated with loss of neurons that produce the neurotransmitter acetylcholine.” § CERVOMED ‘atu
Slide 13: Neflamapimod Reverses Cholinergic Dysfunction and Degeneration
Neflamapimod Reverses Cholinergic Dysfunction and Degeneration § CERVOMED Down Syndrome(DS) mice + 152 transgenic mice that have both DS-like defects during early development and adult- Cholnerals neurons.n.besal torebeein, onset basal forebrain cholinergic Heatnytace Tested OS ce Treated Sasi degen
Slide 14: Neflamapimod Appears to Reverse Basal Forebrain Atrophy, assessed by MRI
Neflamapimod Appears to Reverse Basal § CERVOMED Forebrain Atrophy, assessed by MRI ‘Neflamapimod treatment is associated with increased basal forebrain volume and functional connectivity 15 Early AD patients treatedwith neflamapimod MX aetna omen i was Baseline 2 weeks: Followup treatment wor NOM ~
Slide 15: Phase 2a (AscenD-LB) Clinical Trial Results in Patients with DLB
Phase 2a (”AscenD-LB’) Clinical Trial Results in Patients with DLB § CERVOMED + 91-patient, exploratory, 16-week treatment, double-blind placebo-controlled study in patients with mild-to-moderate DLB Clinical Dementia Rating Sum of Boxes (COR-SB, Total Score = 0-18) + Inthe study, neflamapimod: = Si
Slide 16: AscenD-LB results stratified by presence of AD Co-Pathology
AscenD-LB results stratified by presence of AD Co-Pathology (by plasma ptau181 levels) $ CERVOMED Efficacy results analyzed after stratification presence (44% of patients in study) or absence (66%) of AD co-pathology at study entry, as assessed by prospectively defined cut-off for plasma ptau181 — A
Slide 17: Patients in Phase 2a without AD Co-pathology show substantial response
Patients in Phase 2a without AD Co- pathology show substantial response to § CERVOMED neflamapimod ( Overall study Population Patients Without AD Co- pathology (Plasma ptautaa < cutoff) ra cs NEMO TIO, _bifference! Cohen's | Nemo To, Difference! Cohen's d Placebo. (95%) pralue _effectsize | Placebo
Slide 18: Potential Biomarker Effects Identified in Phase 2a
Potential Biomarker Effects § CERVOMED Identified in Phase 2a EEG: Functional Connectivity in the beta band (13-30 Hz) significantly increased with neflamapimod TID (n=6) vs all placebo (n=17), p=0.03; and vs. placebo TID (n=6), p=0.01. » Plasma Biomarker: In patients without Alzheimer’s related co-
Slide 19: Learnings from Phase 2a Study That Enhance Probability of Success in Phase 2b
Learnings from Phase 2a Study That Enhance $ CERVOMED Probability of Success in Phase 2b + Optimal dose is 40mg TID * Clinical endpoints that can detect effects on both cognitive and motor function (specifically, CDR-SB and TUG) perform better than endpoints that are purely focused on evaluating cog
Slide 20: Phase 2b Study Design
PARTICIPANTS — DLBby consensus criteria, including abnormal DaTscan™ = — Global CDR score of 0.6 or 1.0 AW Py ~ _NoAD co-pathology, assessed by plasma ptau181 INTERVENTION — Randomized on a blinded basis 1:1 to neflamapimod 40mg capsules (n=80) or matching placebo capsules (n=80), TID for 16 weeks,
Slide 21: Major Value Creation Potential with Positive Phase 2b Clinical Trial
Major Value Creation Potential with Positive Phase 2b Clinical Trial $ CeRVOMED Phase 2b success (statistical significance on primary endpoint) will provide a clear path to market in a high value indication » DLBis an indication with high unmet medical need and high commercial return potential + Pha
Slide 22: Key Upcoming Anticipated Milestones/Catalysts
Key Upcoming Anticipated § CERVOMED Milestones/Catalysts 1H 2023 2H 2023 ¥ NIA approves $21M grant for 7 (GRRIMINISES ADELE) Complete enrollment in Phase Phase 2b 2b DLB study (1H) Y Close merger transaction, ¥ Signed merger agreement boom teding ese pba Additional presentations at with Diffusion Ph
Slide 23: Financial Overview
Financial Overview" $ CERVOMED « Approximately 5.7M shares outstanding, all common stock — 0.5M pre-funded warrants; 0.1M out of the money warrants — Other than officers and directors, and certain affiliated trusts, no shareholders subject to contractual lock-ups * CervoMed has cash runway to fund c
Slide 24: Summary
Summary § CERVOMED ifferentiated Approach to Age-related Neurologic Disorders with a Late-Stage Asset Major value creation potential in phase 2b read-out in dementia with Lewy bodies Experienced Management Team and Board of Directors Potential to broaden opportunity through additional indications an
Slide 25: Corporate Overview: Medicines for the Brain
$ CERVOMED “Medicines for the Brain” Corporate Overview NASDAQ: CRVO October 25th, 2023